EGR1 Enhances Lymphangiogenesis via SOX18-Mediated Activation of JAK2/STAT3 Pathway

Yi Yang,1 Yu Li,1 Xu-bo Li,1 Tian-xiao Li,2 Jian Qi,1 Xiang Zhou,1 and Ping Li1

1Department of Microsurgery, Trauma, and Hand Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
2Department of Pharmacy, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, 56 Lingyuanxi Road, Guangzhou 510055, China

Correspondence should be addressed to Xiang Zhou; zhoux87@mail.sysu.edu.cn and Ping Li; liping2@mail.sysu.edu.cn

Received 30 November 2021; Revised 27 December 2021; Accepted 29 December 2021; Published 12 February 2022

Background. Lymphangiogenesis is a process involved in the pathogenesis of many diseases. Identifying key molecules and pathway targeting this process is critical for lymphatic regeneration-associated disorders. EGR1 is a transcription factor, but its function in lymphangiogenesis is not yet known. This study is aimed at exploring the functional activity and molecular mechanism of EGR1 implicated in lymphangiogenesis.

Methods. The CCK-8 method, transwell migration assay, and tube formation assay were used to detect the cell viability, motility, and tube formation of HDLEC cells, respectively. The luciferase reporter assay was applied to detect the impact of EGR1 on SOX18 promoter activity. CHIP assay was used to analyze the direct binding of EGR1 to the SOX18 promoter. qRT-PCR and Western blot analysis were performed to investigate molecules and pathway involved in lymphangiogenesis.

Results. The EGR1 ectopic expression markedly increased the cell growth, mobility, tube formation, and the expression of lymphangiogenesis-associated markers (LYVE-1 and PROX1) in HDLEC cells. EGR1 interacted with the SXO18 gene promoter and transcriptionally regulated the SXO18 expression in HDLEC cells. Silencing of SOX18 abrogated the promotional activities of EGR1 on the cell viability, mobility, tube formation, and LYVE-1/PROX1 expression in HDLEC cells. SOX18 overexpression activated JAK/STAT signaling, which resulted in an increase in lymphangiogenesis in HDLEC cells.

Conclusions. EGR1 can promote lymphangiogenesis, which is mediated by activating the SOX18/JAK/STAT3 cascade. EGR1 may serve as a promising target for the therapy of lymphatic vessel-related disorders.

1. Introduction

Lymphangiogenesis has a key function in a number of disorders, such as hepatic ischemia-reperfusion injury, endometriosis, and inflammatory bowel disease, as well as cancer [1–4]. The progression of lymphangiogenesis involves a number of molecules and pathways. VEGF is suggested to be the most important regulator in lymphatic generation and is wildly used as a therapeutic target against diseases associated with lymphatic generation, such as cancer [5, 6]. However, there are many other factors involved in lymphangiogenesis. Discovering novel mediators controlling lymphangiogenesis is of great importance for developing new strategies for lymphatic remodeling.

EGR1 acts as a transcription factor that binds to the promoter and controls the transcription of multiple pathogenesis-related genes [7–9]. EGR1 has been considered as a therapeutic target for multiple diseases, such as prostate cancer, lymphoid tumors, Alzheimer’s disease, and diabetes [10–13]. EGR1 plays a vital role in many biological programs, including cell survival, cell death, apoptosis, cell motility, and metastasis [9, 14, 15]. EGR1 is demonstrated to have a critical role in angiogenesis as well. For example, Egr1 can enhance angiogenesis by regulating DCC in the cartilage [16]. In early embryonic arrest, miRNA-518b suppresses trophoblast angiogenesis via modulation of the EGR1 expression [17]. Yan et al. have reported that EGR1 can form a feedback loop with CCL2 to promote tumor angiogenesis in gastric cancer [18]. Similar to angiogenesis,
lymphangiogenesis is the process by which new lymphatic vessels are formed [19]. Multiple angiogenesis-related regulators have also been reported to be involved in lymphangiogenesis [5, 19, 20]. Therefore, we hypothesized that EGR1 may also have a crucial function in the progression of lymphangiogenesis.

SOX18 is one of the members of the SOX subfamily, which plays an important role in cell differentiation and cell survival during embryonic development [21]. SOX18 has a crucial function in the formation of lymphatic network [22]. It has been demonstrated that SOX18 promotes lymphatic vessel formation in both embryogenesis and tumor-induced lymphangiogenesis [23]. A previous study reveals that SOX18 is a downstream factor of EGR1 [24], but whether EGR1 regulates lymphangiogenesis via SOX18 is unknown.

This study is aimed at investigating the functional activity of EGR1 in lymphangiogenesis and identifying downstream targets and pathway implicated in EGR1-mediated lymphangiogenesis.

2. Materials and Methods

2.1. Cell Culture. Human dermal lymphatic endothelial cells (HDLEC) were obtained from the Jennio Biotechnology and maintained in EGM-2-MV (Lonza, USA) which was supplemented with EBM-2 (Lonza, USA).

2.2. Transfection. pcDNA3.1-EGR1 and control vector were purchased from GeneCopoeia (Guangzhou, China). siRNA targeting SOX18 and control siRNA were purchased from (GenePharma, Shanghai, Chian). Lipofectamine 2000 (ThermoFisher, USA) was used to transfect DNA plasmid or siRNAs to HDLEC cells.

2.3. Cell Counting Kit-8 Assay. HDLEC cells were plated in 96-well plates. At the indicated time points, 10 μl CCK-8 reagent (Seyotin Biotechnology, Guangzhou, China) was added to triplicate wells and maintained for 2 h, and then the absorbance at 450 nm was measured.

2.4. EdU Staining Assay. HDLEC cells were seeded in 24-well plates. After washed with PBS, 10 μM EdU (RiboBio, Guangzhou, China) in medium without FBS was added to cells. Three hours later, cells were fixed with 4% polyformaldehyde and stained with Apollo solution. The nucleus was stained with DAPI. Stained cells were then visualized using a fluorescence microscopy.

2.5. Migration Assay. HDLEC cells was adjusted to be the density of 1 x 10^6 in medium without serum, and 100 μl cells were plated into the upper compartment of transwell inserts (Corning, USA), while the basolateral chamber was filled with 0.6 ml medium containing 10% FBS. After incubation at 37°C for 24 h, cells were fixed with methanol, followed by staining with crystal violet (0.5%). The number of cells on the bottom of the filter was counted.

2.6. Tube Formation Assay. HDLEC cells (2 x 10^4 cells/well) were plated in 24-well plates precoated with Matrigel (BD Sciences, USA). The plates were maintained at 37°C. Twenty-four hours later, formed tubes were visualized under a light microscope. The tube number at three randomly selected fields was calculated.

2.7. qRT-PCR Assay. Total RNA isolated from HDLEC cells was reverse-transcribed to cDNA with the PrimeScript RT-PCR kit (Seyotin Biotechnology, Guangzhou, China) following the manufacturer’s protocol. PCR was carried out using the SYBR Green PCR mastermix (Seyotin Biotechnology, Guangzhou, China) with following primers: EGR1: 5'-CTGACCAGAGTGCTTTTCTCTG-3' and 5'-TGGGTTCCGGCTCTAGTTAAATG-3'; SOX18: 5'-TTCCATGTCACAGGGCCCTAG-3' and 5'-GACAAGTGGGAACCTCCAG3'; GAPDH: 5'-GGACCTGACCTGGCGTGCTCAGTCTAG-3' and 5'-CCACCACCTGTGTCGTCGTAG-3'. The 2^ΔΔCT formula was used to calculate the gene expression, which was normalized to GAPDH.

2.8. Western Blot. Protein samples isolated from HDLEC cells were separated and transferred to PVDF membrane (Bio-Rad, USA). After incubation with 5% nonfat milk for 1 h, the membrane was incubated with the primary antibodies for 1–2 h. After washing the membranes three times with TBS-Tween solution, the membrane was incubated with secondary antibodies conjugated with HRP for 1 h. Detection with protein bands was performed with the ECL luminescent solution (Seyotin Biotechnology, Guangzhou, China). Antibodies against LYVE-1 and PROX1 were from Abcam (UK). Antibodies against GAPDH, JAK2, phospho-JAK2, STAT3, and phospho-STAT3 (Tyr705) were from Cell Signaling Technology (USA).

2.9. Luciferase Reporter Assay. The SOX18 promoter with EGR1 binding motifs (an 892 bp fragment upstream of ATG start codon) was amplified with primers 5'-GGTGGCCTGGGGCTGGGC-3' and 5'-CTCAGCTGGGGCCGCTGGGAGC-3' and then inserted into a firefly luciferase vector pGL4.10 (pGL4.10-SOX18). For the luciferase reporter assay, HDLEC cells (2 x 10^5 per well) were seeded in a 24-well plate. After the cells were attached overnight, pcDNA3.1-EGR1 (or the control vector) was transfected to HDLEC cells together with pGL4.10-SOX18. For the luciferase reporter assay, HDLEC cells (2 x 10^5 per well) were seeded in a 24-well plate. After the cells were attached overnight, pcDNA3.1-EGR1 (or the control vector) was transfected to HDLEC cells together with pGL4.10-SOX18 (or empty pGL4.10 vector) and Renilla luciferase vector for 48 h. The Dual-Luciferase Reporter Assay System (Promega) was used to detect the firefly and Renilla luciferase activity. The firefly luciferase activity was normalized to Renilla luciferase activity.

2.10. Chromatin Immunoprecipitation (CHIP). The Chromatin Immunoprecipitation (CHIP) Kit (Sigma-Aldrich, USA) was applied to detect the direct binding of EGR1 and SOX18 promoter. Briefly, HDLEC cells were fixed with formaldehyde, and chromatin was broken into 200–500 bp fragments. Chromatin fragments were incubated with anti-EGR1 antibody or control IgG at 4°C overnight. PCR was performed to amplify the bound DNA. Following primers were used for amplifying the promoter region of SOX18: 5'-CGGGAGGAGGGCGG
Figure 1: Overexpression of EGR1 induces lymphangiogenesis. (a) The protein expression of EGR1 was examined by Western blot in HDLEC cells following the EGR1 overexpression. (b) HDLEC cell viability was accessed by the CCK-8 method after EGR1 upregulation. (c) HDLEC cell motility was detected by migration assay after the EGR1 overexpression. Scale bar = 50 μm. (d) The tube formation of HDLEC cells was analyzed by tube formation assay after the overexpression of EGR1. Scale bar = 50 μm. (e) The protein expressions of lymphangiogenesis-related markers (LYVE-1 and PROX1) were addressed by Western blot in HDLEC cells after ectopic expression of EGR1. *P < 0.05, **P < 0.01.
Figure 2: The overexpression of SOX18 promotes lymphangiogenesis. (a) The SOX18 protein expression was investigated by Western blot in HDLEC cells following the overexpression of SOX18. (b) HDLEC cell viability was determined by EdU staining assay following the overexpression of SOX18. Scale bar = 50 μm. (c) HDLEC cell motility was detected by migration assay following the overexpression of SOX18. Scale bar = 50 μm. (d) The tube formation of HDLEC cells was analyzed by tube formation assay following SOX18 upregulation. Scale bar = 50 μm. (e, f) LYVE-1 and PROX1 mRNA and protein levels were determined by qRT-PCR assay (e) and Western blot analysis (f) in HDLEC cells following the overexpression of SOX18. *P < 0.05, **P < 0.01.
CCCGGAC-3′ and 5′-TCCAGCTGGGCGCGGCCTG GGC-3′. Products of PCR were determined by electrophoresis.

2.11. Statistical Analysis. All data were shown as the mean ± standard deviation. Statistical comparisons were performed with Student’s t-test (two groups) or one-way ANOVA (more than two groups). Statistically significance was considered as P < 0.05.

3. Results

3.1. Overexpression of EGR1 Enhances HDLEC Cell Growth, Migration, and Tube Formation. To investigate the effect of EGR1 on lymphangiogenesis, we overexpressed EGR1 in HDLEC cells. The results confirmed that there was increased EGR1 expression in EGR1-overexpressed HDLEC cells (Figure 1(a) and Figure S1). We then access the influence of EGR1 on HDLEC cell growth. The cell viability of EGR1-overexpressed HDLEC cells was greatly increased as compared with control cells (Figure 1(b)). Transwell migration assay displayed that the overexpression of EGR1 highly elevated the migratory activity of HDLEC cells (Figure 1(c)). The number of tubes was also highly elevated in HDLEC cells after transfection with EGR1 (Figure 1(d)). In consistent with this result, the levels of LYVE-1 and PROX1, two key regulators of lymphangiogenesis, were also raised (Figure 1(e) and Figure S2). Collectively, these data show that EGR1 can enhance the viability, motility, and tube formation in HDLEC cells.

3.2. Ectopic Expression of SOX18 Enhances HDLEC Cell Viability, Motility, and Tube Formation. EGR1 is an upstream regulator of SOX18, which regulates cell survival, differentiation, and migration [24]. Consistently, we found that EGR1 could increase the SOX18 expression at both mRNA and protein levels (Figure 2(a)). Next, we examined the potential activity of SOX18 in HDLEC cells. The number of EdU-positive cells was elevated in SOX18-overexpressing HDLEC cells as demonstrated by EdU staining (Figure 2(b)). Moreover, the migration activity of SOX18-overexpressing HDLEC cells was also increased (Figure 2(c)). In addition, the tube formation was also increased in SOX18-overexpressing HDLEC cells compared with control cells (Figure 2(d)). The levels of LYVE-1 and PROX1 proteins were augmented in HDLEC cells overexpressing SOX18 compared with control cells (Figure 2(e)). Collectively, these data indicate a promotional activity of SOX18 in regulating the viability, migration, and tube formation in HDLEC cells.

3.3. EGR1 Regulates the Transcription of SOX18. EGR1 is a transcription factor which regulates gene transcription via interacting with the target gene promoter. To investigate whether EGR1 transcriptionally regulated SOX18 in HDLEC cells, the luciferase reporter assay was performed with the
SOX18 promoter. EGR1 could remarkably increase the luciferase activity of SOX18 promoter (Figure 3(a)). The direct binding of EGR1 to SOX18 promoter is required for the modulation of SOX18 by EGR1. To verify that there was an interaction between EGR1 and SOX18 promoter, CHIP assay was performed. As shown in Figure 3(b), EGR1 antibody could bind to the SOX18 promoter (Figure 3(b)). Additionally, silencing of EGR1 deceased SOX18 protein level (Figure 3(c)). In all, these results suggest that EGR1 is a transcription regulator of SOX18.
Figure 5: SOX18 triggers lymphangiogenesis via the JAK2/STAT3 pathway. (a) The expression and phosphorylation of JAK2 and STAT3 in HDLEC cells after the overexpression of SOX18. (b, c) Treatment with ruxolitinib inhibited the motility (b) and tube formation (c) in HDLEC cells that was increased by the SOX18 overexpression. Scale bar = 50 μm. (d) Treatment with ruxolitinib restrained SOX-18-mediated promotion in the LYVE-1/PROX1 expression. *P < 0.05; **P < 0.01.
3.4. EGR1 Promotes Lymphangiogenesis via Activation of SOX18. Next, we investigated whether SOX18 modulation contributed to EGR1-induced lymphangiogenesis. The ectopic expression of EGR1 increased HDLEC cell viability, but this effect was counteracted by siRNA-mediated silencing of SOX18 (Figure 4(a)). Migration assay revealed that transfection of EGR1 enhanced the migratory capability of HDLEC cells, which could be reduced by SOX18 knockdown (Figure 4(b)). Moreover, depletion of SOX18 attenuated EGR1 overexpression tube formation in HDLEC cells (Figure 4(c)). Silencing of SOX18 abolished the enhanced effect of EGR1 overexpression on LYVE-1 and PROX1 expressions (Figures 4(d) and 4(e)). Collectively, these data indicate that EGR1 induces lymphangiogenesis via upregulation of SOX18.

3.5. SOX18 Induces Lymphangiogenesis via the JAK2/STAT3 Pathway. The JAK2/STAT3 pathway is participated in the progression of lymphangiogenesis, and SOX18 has been reported to regulate this pathway [25]. Therefore, we investigated whether SOX18-mediated JAK2/STAT3 activation was involved in lymphangiogenesis. Upregulation of SOX18 elevated the levels of p-JAK2 and p-STAT3, but did not significantly affect their protein expression (Figure 5(a)). To further investigate the impact of JAK2/STAT3 pathway on lymphangiogenesis, the JAK2/STAT3 pathway inhibitor ruxolitinib was applied. While the overexpression of SOX18 markedly increased the migratory activity of HDLEC cells, treatment with ruxolitinib reduced the increase (Figure 5(b)). Tube formation assay also showed that ruxolitinib decreased tube formation that was elevated by the SOX18 overexpression (Figure 5(c)). In addition, the promotional effect of the SOX18 overexpression on the levels of LYVE-1 and PROX1 was counteracted by the treatment of ruxolitinib (Figure 5(d)). Moreover, ruxolitinib also reduced EGR1-induced LYVE-1 and PROX1 expression (Figure S4). Together, these data imply that SOX18 mediated activation of JAK2/STAT3 contributes to lymphangiogenesis promotion.

4. Discussion

Lymphatic system is crucial for the homeostasis and its aberration associated with the progression of multiple diseases [1–4]. Therefore, discovering the key factors controlling the growth of lymphatic tubes should have great treatment benefits. EGR1 is an important regulator in angiogenesis, but its function in lymphangiogenesis is not well known. The current study showed that EGR1 had a stimulated activity in lymphangiogenesis. Moreover, our data revealed that EGR1 induced lymphangiogenesis via activation of SOX18/JAK2/STAT3 pathway.

Blood and lymphatic networks are necessary for delivering gases, fluids, molecules, as well as cells within the vertebrate body [19, 26, 27]. Both blood and lymphatic structures are lined with endothelial cells that communicate with the extracellular environments [28]. Angiogenesis and lymphangiogenesis often occur pathological conditions such as inflammation, tissue injury, and tumor growth [29], and both of them are responded to multiple inducers or inhibitors [19, 30, 31]. A number of studies have been reported that factors involved in angiogenesis also have an effect on lymphangiogenesis. For instance, MetAp2 has been reported to have a dual role in the formation of blood and lymphatic vessels [5]. EGR1 has been demonstrated to have a critical role in blood vessel formation [16–18]. Interestingly, we showed that EGR1 could markedly increase the proliferation, motility, and tube formation of HDLEC cells, indicating a promoting activity of EGR1 in lymphatic generation. Hence, our data and previous results suggest that EGR1 has a dual role in both angiogenesis and lymphangiogenesis.

SOX18 is one of the members of the Sox subfamily, which has a crucial function in the formation of lymphatic network [22]. Using molecular, cellular, and genetic assays, SOX18 is shown to be important for the differentiation of lymphatic endothelial cells in mice [32]. Aberration of SOX18 at genetic level inhibits melanoma lymphangiogenesis in mice [33]. A recent study also reported that SOX18 interacts with VEGFC to regulate the lymphatic formation in zebrafish [34]. Consistently, we found that SOX18 could increase the cell growth, motility, and tube formation of HDLEC cells. EGR1 is a transcription regulator, and its binding to the promoter region of targets is required for its regulation. Our data showed that EGR1 enhanced the promoter activity of SOX18 and interacted with the promoter of SOX18 in HDLEC cells, indicating that EGR1 is a transcriptional activator of SOX18, which was consistent with a previous study [24]. Moreover, knockdown of SOX18 revered the promotional effect of EGR1 on lymphangiogenesis, confirming the contribution of SOX18 in EGR1-induced formation of lymphatic vessels.

The JAK/STAT3 pathway modulates many processes, such as cell viability, cell motility, and angiogenesis [35–37]. Recent studies also revealed that the JAK/STAT3 pathway is also implicated in lymphatic remodeling. It has been reported that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) repress tumor lymphangiogenesis in lung cancer via the JAK/STAT3 cascade [38]. IL-6 has been also showed to promote lymphangiogenesis via activation of the JAK/STAT3 signaling [39, 40]. SOX18 has been shown to regulate the JAK/STAT3 pathway to promote laryngeal carcinoma cell growth, cell motility, and invasion [25]. Consistently, we found that the ectopic expression of SOX18 increased the phosphorylation of JAK2 and STAT3. Importantly, treatment with JAK2/STAT3 inhibitor abolished the promotion in HDLEC cell motility and tube formation induced by SOX18. These findings revealed that SOX18 induced lymphangiogenesis via the JAK/STAT3 signaling.

5. Conclusions

Our results showed that the ectopic expression of EGR1 enhances HDLEC cell viability, motility, and tube formation via SOX18-mediated JAK2/STAT3 activation. Therefore, EGR1 may serve as a novel target for treating diseases involved in lymphatic generation.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yi Yang and Yu Li were considered as the first authors since authors contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81873530) and Project of Guangdong Provincial Science and Technology Department (2014A010107008).

Supplementary Materials

Figure S1: the mRNA expression of EGR1 in HDLEC cells overexpressing EGR1 was determined by qRT-PCR. Figure S2: the mRNA expressions of LYVE-1 and PROX1 in HDLEC cells overexpressing EGR1 were examined by qRT-PCR. Figure S3: the mRNA level of SOX18 in HDLEC cells overexpressing SOX18 was detected by qRT-PCR. Figure S4: ruxolitinib also reduced EGR1-induced LYVE-1 and PROX1 expression. (Supplementary Materials)

References

[1] M. G. Bae, J. Hwang-Bo, D. Y. Lee, Y. H. Lee, and I. S. Chung, “Effects of 6,8-diprenylgenistein on VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model,” International Journal of Molecular Sciences, vol. 22, no. 2, 2021.

[2] K. Hattori, Y. Ito, M. Honda et al., “Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice,” Journal of Pharmacological Sciences, vol. 143, no. 4, pp. 255–263, 2020.

[3] K. Hosono, K. Kojo, S. Narumiya, M. Majima, and Y. Ito, “Prostaglandin E receptor EP4 stimulates lymphangiogenesis to promote mucosal healing during DSS-induced colitis,” Biomedicine & Pharmacotherapy, vol. 128, article 110264, 2020.

[4] S. Nakamoto, Y. Ito, N. Nishizawa et al.,”Lymphangiogenesis and accumulation of reparative macrophages contribute to liver repair after hepatic ischemia-reperfusion injury,” Angiogenesis, vol. 23, no. 3, pp. 395–410, 2020.

[5] R. Esa, E. Steinberg, D. Dror et al., “The role of methionine aminopeptidase 2 in lymphangiogenesis,” International Journal of Molecular Sciences, vol. 21, no. 14, 2020.

[6] L. Alderfer, A. Wei, and D. Hanjava-Putra, “Lymphatic tissue engineering and regeneration,” Journal of Biological Engineering, vol. 12, p. 32, 2018.

[7] M. Park, S. H. Park, H. Park, H. R. Kim, H. J. Lim, and H. Song, "ADAMTS-1: a novel target gene of an estrogen-induced transcription factor, EGR1, critical for embryo implantation in the mouse uterus," Cell & Bioscience, vol. 11, no. 1, p. 153, 2021.

[8] Y. Yang, F. Wu, J. Zhang et al., “EGR1 interacts with DNMT3L to inhibit the transcription of miR-195 and plays an anti-apoptotic role in the development of gastric cancer," Journal of Cellular and Molecular Medicine, vol. 23, no. 11, pp. 7372–7381, 2019.

[9] J. Zhao, H. Li, and M. Yuan, “EGR1 promotes stemness and predicts a poor outcome of uterine cervical cancer by inducing SOX9 expression,” Genes & Genomics, vol. 43, no. 5, pp. 459–470, 2021.

[10] X. Qin, Y. Wang, and H. K. Paudel, “Early growth response 1 (Egr-1) is a transcriptional activator of β-secretase 1 (BACE-1) in the brain,” The Journal of Biological Chemistry, vol. 291, no. 42, pp. 22276–22287, 2016.

[11] N. Shen, X. Yu, F. Y. Pan, X. Gao, B. Xue, and C. J. Li, “An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism,” The Journal of Biological Chemistry, vol. 286, no. 16, pp. 14508–14515, 2011.

[12] F. Bouchard, S. D. Belanger, K. Biron-Pain, and Y. St-Pierre, “EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth,” Blood, vol. 116, no. 5, pp. 759–766, 2010.

[13] D. Gitenay and V. T. Baron, “Is EGR1 a potential target for prostate cancer therapy?,” Future Oncology, vol. 5, no. 7, pp. 993–1003, 2009.

[14] S. Shao, M. Ju, J. Lei et al., “Egr-1 inhibits colon cancer cell proliferation, migration and invasion via regulating CDK1 at the transcriptional level,” Oncology Reports, vol. 46, no. 2, 2021.

[15] Y. Ye, M. Liu, L. Tang et al., “Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis,” Arthritis Research & Therapy, vol. 21, no. 1, p. 92, 2019.

[16] J. Sheng, D. Liu, X. Kang, Y. Chen, K. Jiang, and W. Zheng, “Egr-1 increases angiogenesis in cartilage via binding Netrin-1 receptor DCC promoter,” Journal of Orthopaedic Surgery and Research, vol. 13, no. 1, p. 125, 2018.

[17] W. Yang, Z. Lu, Z. Zhi et al., “Increased miRNA-518b inhibits trophoblast migration and angiogenesis by targeting EGR1 in early embryonic arrest,” Biology of Reproduction, vol. 101, no. 4, pp. 664–674, 2019.

[18] J. Yan, Y. Gao, S. Lin, Y. Li, L. Shi, and Q. Kan, “EGR1-CCL2 feedback loop maintains epithelial-mesenchymal transition of cisplatin-resistant gastric cancer cells and promotes tumor angiogenesis,” Digestive Diseases and Sciences., 2021.

[19] R. H. Adams and K. Alitalo, “Molecular regulation of angiogenesis and lymphangiogenesis,” Nature Reviews Molecular Cell Biology., vol. 8, no. 6, pp. 464–478, 2007.

[20] B. K. McColl, S. A. Stacker, and M. G. Achen, “Molecular regulation of the VEGF family inducers of angiogenesis and lymphangiogenesis,” Acta pathologica, microbiologica, et immunologica Scandinavica Section C, Immunology, vol. 112, no. 7-8, pp. 463–480, 2004.

[21] Z. Y. She and W. X. Yang, “SOX family transcription factors involved in diverse cellular events during development,” European Journal of Cell Biology, vol. 94, no. 12, pp. 547–563, 2015.

[22] Z. Miao, X. Deng, P. Shuai, and J. Zeng, “Upregulation of SOX18 in colorectal cancer cells promotes proliferation and correlates with colorectal cancer risk,” Onco Targets and Therapy, vol. 11, pp. 8481–8490, 2018.
[23] M. Klaus, N. Prokoph, M. Girbig et al., “Structure and decoy-mediated inhibition of the SOX18/Prox 1-DNA interaction,” *Nucleic Acids Research*, vol. 44, no. 8, pp. 3922–3935, 2016.

[24] I. Petrovic, N. Kovacevic-Grucic, and M. Stevanovic, “Early growth response protein 1 acts as an activator of SOX18 promoter,” *Experimental & Molecular Medicine*, vol. 42, no. 2, pp. 132–142, 2010.

[25] Y. Xu, Q. Zhang, J. Zhou, Z. Li, J. Guo, and W. Wang, “Down-regulation of SOX18 inhibits laryngeal carcinoma cell proliferation, migration, and invasion through JAK2/STAT3 signaling,” *Bioscience Reports*, vol. 39, no. 7, 2019.

[26] L. Knezevic, M. Schaupper, S. Mühleder et al., “Engineering blood and lymphatic microvascular networks in fibrin matrices,” *Frontiers in Bioengineering and Biotechnology*, vol. 5, p. 25, 2017.

[27] J. Schneider, M. Pultar, and W. Holnthoner, “Ex vivo engineering of blood and lymphatic microvascular networks,” *Vascular Biology*, vol. 1, no. 1, pp. H17–H22, 2019.

[28] E. Gordon, L. Schimmel, and M. Frye, “The importance of mechanical forces for in vitro endothelial cell biology,” *Frontiers in Physiology*, vol. 11, p. 684, 2020.

[29] B. A. Corliss, M. S. Azimi, J. M. Munson, S. M. Peirce, and W. L. Murfee, “Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis,” *Microcirculation*, vol. 23, no. 2, pp. 95–121, 2016.

[30] M. A. A. al-Rawi, R. E. Mansel, and W. G. Jiang, “Molecular and cellular mechanisms of lymphangiogenesis,” *European Journal of Surgical Oncology*, vol. 31, no. 2, pp. 117–121, 2005.

[31] M. Francois, A. Caprini, B. Hosking et al., “Sox18 induces development of the lymphatic vasculature in mice,” *Nature*, vol. 456, no. 7222, pp. 643–647, 2008.

[32] T. Duong, S. T. Proulx, P. Luciani et al., “Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis and metastasis of melanoma in mice,” *Cancer Research*, vol. 72, no. 12, pp. 3105–3114, 2012.

[33] S. Cermenati, S. Moleri, C. Neyt et al., “Sox18 genetically interacts with VegfC to regulate lymphangiogenesis in zebrafish,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 6, pp. 1238–1247, 2013.

[34] C. Song, B. Fan, and Z. Xiao, "Overexpression of ALK4 inhibits cell proliferation and migration through the inactivation of JAK/STAT3 signaling pathway in glioma," *Biomedicine & Pharmacotherapy*, vol. 98, pp. 440–445, 2018.

[35] P. Ji, L. Wang, J. Liu et al., “Knockdown of RPL34 inhibits the proliferation and migration of glioma cells through the inactivation of JAK/STAT3 signaling pathway,” *Journal of Cellular Biochemistry*, vol. 120, no. 3, pp. 3259–3267, 2019.

[36] C. Xue, J. Xie, D. Zhao et al., “The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model,” *Cell Proliferation*, vol. 50, no. 1, 2017.

[37] Y. Zhang, X. Yang, H. Liu, M. Cai, and Y. Shentu, “Inhibition of tumor lymphangiogenesis is an important part that EGFR-TKIs play in the treatment of NSCLC,” *Journal of Cancer*, vol. 11, no. 1, pp. 241–250, 2020.

[38] G. Zhao, G. Zhu, Y. Huang et al., "IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer," *Oncology Reports*, vol. 35, no. 3, pp. 1787–1795, 2016.

[40] B. J. O’Brien, H. A. Singer, A. P. Adam, and R. G. Ginnan, "CaMKIIδ is upregulated by pro-inflammatory cytokine IL-6 in a JAK/STAT3-dependent manner to promote angiogenesis," *FASEB Journal*, vol. 35, no. 4, article e21437, 2021.